Bristol-Myers Squibb (BMY) is ranked 5th among the best pharma stocks to buy according to hedge funds. The company boasts a ...
19h
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical ...
We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...
KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including ...
The Latest research report offers an in-depth analysis of the Healthcare Nanotechnology Market, highlighting key trends in product segmentation, company dynamics, revenue streams, market share, recent ...
Bristol-Myers Squibb has agreed a $74 billion deal to merge with Celgene in a deal that will boost its presence in oncology and immunology and make it the fourth-largest drugmaker.
Celgene is the latest pharma company to recruit IBM’s artificial intelligence powerhouse Watson, this time to help monitor drug safety. The project’s goal is to create a cognitive computing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback